FDA supports early use of Lily’s breast cancer treatment, Verzenio
Eli Lilly has picked up yet another FDA approval for CDK4/6 inhibitor Verzenio – its third in five months – as it tries to chase down Pfizer’s category-leading Ibrance. The US regulator has given the nod to Verzenio for use in combination with an aromatase inhibitor as initial endocrine-based therapy for women with breast cancer